According to the recommended HER2 testing guidelines for gastric cancer, 36 (11.8%, 18 IHC 3+ and 18 IHC 2+, and HER2 amplified) cases were interpreted as HER2-positive and 270 (88.2%) cases were interpreted as HER2-negative. Here, ERBB2 is linked to gastric cancer.